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Abstract 
OBJECTIVES Driveline infections are one of the most common and important complications in 
patients with left ventricular assist device (LVAD). One of the causes favouring the development of 
this complication is the traumatism of the exit site, which occurs in response to movement of the 
driveline. In this work, we present a simple and feasible method to immobilize the driveline at the 
level of the exit site. 
METHODS From April 2013 until November 2013, 6 patients underwent implantation of 
HeartWare LVAD (HVAD) for an end-stage heart failure. When the patient has begun to mobilize 
after the implantation of the device, we have combined the use of two components with the aim of 
securing the driveline to the patient's skin: a StatLock system and a silicone suture. 
RESULTS No case of local traumatism and no case of local infection at the driveline were 
observed during the follow-up. No patient reported pain or swelling at the driveline exit site. All 
patients were satisfied with their quality-of-life and they do not report any limitations in their daily 
activities. 
CONCLUSIONS One of the major long-term complications in patients with LVAD is the 
development of infections of the exit site of the driveline. The trauma of this skin region promotes 
the onset and maintenance of an inflammatory process and local infectious. Avoiding excessive 
mobilization of the driveline is likely to reduce the incidence of infections of the exit site and 
improve the quality-of-life. 
INTRODUCTION 
Driveline infections are one of the most common and important complications in patients with left 
ventricular assist device (LVAD) [1–3]. Currently there are not any new systems for energy 
transmission which do not involve the presence of a percutaneous cable, exposing the patient to a 
risk of exit-site infection. Some studies on the use of alternative supply for LVAD are currently 
underway, such as transcutaneous energy transmission, but their clinical application is still far [4]. 
One of the causes favouring the development of exit-site infections is the traumatism of the exit 
site, which occurs in response to movement of the driveline. Several authors have described the role 
of local trauma in the subsequent development of infection [1, 3]. In this work, we present a simple 
and feasible method of immobilizing the driveline at the level of the exit site using a non-traumatic 
device (StatLock, Bard Limited Forest House, Crawley, West Sussex, UK) and a silicone suture 
wing, part from a central venous catheter set (Arrow International, Inc., PA, USA). We used this 
method in 6 patients supported by HeartWare (HeartWare International, Inc., MA, USA) LVAD as 
bridge to decision. 
 
 
MATERIALS AND METHODS 
From April 2013 until November 2013, 6 patients underwent implantation of HeartWare LVAD 
(HVAD) for an end-stage heart failure. All patients were in Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) level III. The mean age was 57.5 years (39–65 years). 
All patients were male. In all patients, the implantation was done through a median longitudinal 
sternotomy and the driveline was tunnellized on the right side of the abdominal wall just a few 
centimetres under the umbilicus. To immobilize the driveline, we have combined the use of two 
components: a StatLock system adhering to the skin at the point chosen for attachment and a 
silicone suture wing taken from a central venous catheter (CVC) set (7 or 8.5 French, but the second 
is better), routinely used for fixing the catheter at the skin. 
The StatLock device was placed on the skin ∼4–7 cm from the exit site (also depending on the need 
and comfort of the patient) (Fig. 1). The driveline was ensured at the level of the StatLock using the 
silicon suture wing. The driveline was locked into the suture wings using a silk thread (it is possible 
to use a silicone tape in contact with the driveline, to avoid a traumatism of the suture on the cable) 
(Fig. 2). The suture wing was connected to the StatLock using two plastic closures. 
 
Figure 1: 
Correct positioning of the device. 
 
Figure 2: 
Positioning of the suture wing on the cable. A strip of soft material is interposed appropriately to 
prevent decubitus of the silk thread on the driveline. 
It is possible to mobilize the driveline from the StatLock allowing an easy mobilization and 
disinfection of the exit site, opening the plastic closures (Fig. 3); routinely, the medication was 
carried out using chlorine-based disinfectants and placing a protective-disk chlorhexidine based. 
 
Figure 3: 
Fixing system of the suture wing to StatLock. 
RESULTS 
All patients survived after the LVAD implantation and they were discharged from the hospital. The 
mean follow-up was 120 days (23–224 days). Before using this device, which began in April 2013, 
we recorded 2 cases of driveline infections out of 11 patients supported by HVAD (November 2010 
to April 2013) with an incidence of 18.2%. From April 2013 until now we did not record driveline 
infection events. Both prior to the introduction and after, the disinfection protocol of the wound and 
the exit site dressing were the same. The exit site is disinfected with chlorine-based products and is 
covered with a protective disk chlorhexidine based. The exit site is further protected by applying a 
transparent film dressing such as Tegaderm. 
The StatLock device has been used in all cases in order to fix the driveline after a complete 
mobilization of the patient. The movement of the bag containing the controller and batteries 
leverages at the exit site. Basically, this device has the task of moving the fulcrum of the lever a few 
inches away from the exit site. No case of local traumatism and no case of local infection at the 
driveline were observed during the follow-up. No patient reported pain or swelling at the driveline 
exit site. Being a device adhering to the skin, StatLock does not cause pain to the patient in case of 
excessive traction with detachment. The StatLock device was changed every 7–10 days. We did not 
detect damage to the driveline. All patients were satisfied with their quality-of-life; the amplitude of 
motion of the driveline is reduced to a few centimetres without causing particular limitations in 
normal daily activities such as driving, showering, etc. Patients who have tried our device reported 
no particular limitations in their daily activities, contrary to patients implanted before April 2013. In 
some cases, the patients reported that they did not remember having a percutaneous cable, because 
the immobilization of the driveline at the level of the exit site did not cause traction resulting in 
redness and inflammation. 
DISCUSSION 
Although there are commercial LVAD with alternative locations of the driveline, such as a skull-
mounted pedestal in Jarvik et al. [5], the majority of devices present a percutaneous driveline 
localized at the abdominal level. 
The importance of a stabilization of the driveline to avoid excessive trauma of the exit site [1–3] is 
described in the literature. Zierer et al. [1] in their multivariate analysis recognize in the exit-site 
trauma an independent factor favouring the development of infection. Goldstein et al.[2], in their 
subanalysis of the INTERMACS registry, showed that the freedom of exit-site infection event is 
81% at 1 year after implant, according to the last INTERMACS report. Their study reported that 
age is the only multivariate predictor of percutaneous site infection; for every decrease in 10 years 
of age, the risk of infection rose by 20%. Our cohort of patients is within the first two groups 
identified by Goldstein (<50 years and 50–70 years) with an increased risk of developing exit-site 
infections. This is probably due to more physical activity in young patients than in elderly, resulting 
in greater exit-site driveline trauma. Choi et al. [6] recognized the importance of the immobility of 
the driveline to promote healing of the exit site, even assuming the use of antimicrobial substances 
on the surface of the driveline to prevent early infections and facilitate ingrowth of tissue. 
There is, therefore, the need to avoid excessive movements of the driveline, in order to prevent skin 
lesions with risk of bacterial overinfection. 
Currently, there are no commercially specific devices for locking the driveline to the skin in patients 
supported by HeartWare; our simple and feasible method may help to reduce the risk of local 
trauma and improve the quality-of-life of the patient. No difficulty has been experienced with the 
management of the exit-site's medications or from the home nurse who has the task of dressings 
patients after discharge home. 
This fixing method has a very low cost. The price of the CVC set is ∼18 dollars (in our case, the 
suture wing is not routinely used by our anaesthesiologists and was recovered from sterile sets) and 
StatLock is available to us at the cost of ∼5 dollars. The use of these components in our method is 
off-label, not on the data sheet of the products. 
CONCLUSION 
Currently, one of the most important limitations of the ventricular assist device is the energy supply 
of the device that requires a percutaneous drive-line. While waiting for new forms of energy 
transmission such as transcutaneous energy transmission systems, our method is configured as a 
valuable aid for the prevention of traumatism of the exit site, favouring a lower incidence of 
infections and promoting a better quality-of-life of the patient. 
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